Trial Profile
Treatment of Chronic Active Antibody-mediated Rejection With Bortezomib in Kidney Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Immunoglobulins
- Indications Transplant rejection
- Focus Therapeutic Use
- Acronyms TRIBUTE
- 14 Sep 2020 Status changed from active, no longer recruiting to completed.
- 18 Oct 2019 Planned End Date changed from 1 Feb 2020 to 1 Jul 2020.
- 18 Oct 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Jul 2020.